These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 31481801)
1. Time from autologous to allogeneic hematopoietic stem cell transplantation impacts post-transplant outcomes in multiple myeloma. Fiorenza S; Routledge D; Collins J; Shipton M; Harrison S; Bajel A; Cavet J; Tholouli E; Gauthier J; Ritchie D Bone Marrow Transplant; 2020 Jun; 55(6):1172-1174. PubMed ID: 31481801 [No Abstract] [Full Text] [Related]
2. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy. Kyle RA Ann Oncol; 2000; 11 Suppl 1():55-8. PubMed ID: 10707780 [TBL] [Abstract][Full Text] [Related]
3. Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. El-Jawahri A; Chen YB; Brazauskas R; He N; Lee SJ; Knight JM; Majhail N; Buchbinder D; Schears RM; Wirk BM; Wood WA; Ahmed I; Aljurf M; Szer J; Beattie SM; Battiwalla M; Dandoy C; Diaz MA; D'Souza A; Freytes CO; Gajewski J; Gergis U; Hashmi SK; Jakubowski A; Kamble RT; Kindwall-Keller T; Lazarus HM; Malone AK; Marks DI; Meehan K; Savani BN; Olsson RF; Rizzieri D; Steinberg A; Speckhart D; Szwajcer D; Schoemans H; Seo S; Ustun C; Atsuta Y; Dalal J; Sales-Bonfim C; Khera N; Hahn T; Saber W Cancer; 2017 May; 123(10):1828-1838. PubMed ID: 28102896 [TBL] [Abstract][Full Text] [Related]
4. Advances in the autologous and allogeneic transplantation strategies for multiple myeloma. Nishihori T; Alsina M Cancer Control; 2011 Oct; 18(4):258-67. PubMed ID: 21976244 [TBL] [Abstract][Full Text] [Related]
7. Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma. Arora M; McGlave PB; Burns LJ; Miller JS; Barke JN; Defor TE; Weisdorf DJ Bone Marrow Transplant; 2005 Jun; 35(12):1133-40. PubMed ID: 15834435 [TBL] [Abstract][Full Text] [Related]
8. Poor autologous mobilization status does not impact on hematological recovery but affects outcome after allogeneic stem cell transplant for lymphoma and myeloma. Crocchiolo R; Chabannon C; El-Cheikh J; Esterni B; Lemarié C; Fürst S; Castagna L; Bouabdallah R; Ladaique P; Coso D; Schiano JM; Stoppa AM; Rey J; Ivanov V; Aurran T; Faucher C; Blaise D; Calmels B Leuk Lymphoma; 2013 Feb; 54(2):417-20. PubMed ID: 22702654 [No Abstract] [Full Text] [Related]
9. Trends and outcomes in allogeneic hematopoietic stem cell transplant for multiple myeloma at Mayo Clinic. Mir MA; Kapoor P; Kumar S; Pandey S; Dispenzieri A; Lacy MQ; Dingli D; Hogan W; Buadi F; Hayman S; Gandhi M; Gertz MA Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):349-357.e2. PubMed ID: 25958193 [TBL] [Abstract][Full Text] [Related]
10. Autologous and allogeneic transplants for multiple myeloma. Barlogie B; Jagannath S; Vesole D; Tricot G Semin Hematol; 1995 Jan; 32(1):31-44. PubMed ID: 7878476 [No Abstract] [Full Text] [Related]
11. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Qazilbash MH; Saliba R; De Lima M; Hosing C; Couriel D; Aleman A; Roden L; Champlin R; Giralt SA Cancer; 2006 Mar; 106(5):1084-9. PubMed ID: 16456814 [TBL] [Abstract][Full Text] [Related]